AGC (5201) investor relations material

Executive summary

• FY2025 saw flat to slightly lower net sales at ¥2,058.8 billion, while operating profit rose year-over-year, mainly due to improvements in the Automotive segment and effective pricing policies.

• Profit attributable to owners of the parent improved significantly, reversing prior-year losses, with ROE rising to 4.7%.

• Major impairments in Display (2022) and Biopharmaceutical CDMO (2024) previously weighed on results, but initiatives and the absence of prior-year losses have turned profitability around.

• FY2026 outlook anticipates operating profit growth, driven by Life Science recovery and continued improvements in core businesses.

• The global economic environment in FY2025 was marked by moderate recovery, with US growth, stagnation in Europe/China, and moderate gains in Japan.

Financial highlights

• FY2025 net sales were ¥2,058.8 billion, down ¥8.8 billion year-over-year, with operating profit up ¥1.6 billion to ¥127.5 billion.

• Profit before tax rebounded to ¥124.8 billion from a prior-year loss, and profit attributable to owners was ¥69.2 billion, up ¥163.2 billion.

• Operating profit margin was 6.2%; gross profit was ¥500.4 billion with a 24.3% margin.

• Free cash flow was ¥96.1 billion, and CapEx was ¥251.3 billion.

• Basic EPS reached ¥326.20, and total assets increased to ¥2,950.1 billion.

Outlook and guidance

• FY2026 forecasts net sales of ¥2,200 billion (+¥141.2 billion YoY) and operating profit of ¥150 billion (+¥22.5 billion YoY).

• ROE is expected to improve to 5.2%, with profit attributable to owners projected at ¥77.0 billion and EPS at ¥363.12.

• Life Science segment is projected to reduce losses significantly, with strategic business OP forecast at ¥80 billion.

• CapEx for 2026 is forecast at ¥190 billion, with major expansion investments completed in 2025.

• Dividend forecast for FY2026 is maintained at ¥210 per share.